- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03349931
Prospective Multicenter Evaluation of the MycoGenie Kit for the Diagnosis of Invasive Aspergillosis (MYCOGENIE)
Prospective Multicenter Evaluation of the MycoGenie Kit for the Diagnosis of Invasive Aspergillosis in Hematological Patients
Study Overview
Status
Intervention / Treatment
Detailed Description
Accurate diagnosis of invasive pulmonary aspergillosis (IPA) in patients at high risk of invasive fungal infection remains challenging due to difficulties in differentiating IPA from pulmonary infections caused by other molds or bacteria on clinical and radiological grounds. Therefore, culture-based microbiological diagnosis is of primary importance but requires semi-invasive or invasive procedures, such as bronchoalveolar Lavage (BAL) or computed-tomography (CT)-guided needle biopsy.
Alternate diagnostic methods include the detection of biomarkers, such as fungal antigens (Aspergillus galactomannan [GM]) or DNA released by Aspergillus hyphae in host tissues. These biomarkers are well recognized as early IPA predictors Recently, several clinical evaluations to detect Aspergillus DNA, either in respiratory or in blood-based samples, have clearly shown the diagnostic value of this biomarker. In addition, methodological recommendations have been established for PCR protocols, and different standardized Aspergillus quantitative PCR (qPCR) kits have been commercialized. These recent advances show that PCR is now mature for routine use in clinical settings.
Another issue is the emergence of aspergillosis due to azole-resistant isolates. Acquired azole resistance in A. fumigatus has been reported since 1997 and has emerged in many countries, particularly in Europe, as well as on other continents. In some instances, acquired resistance may be driven by antifungal selection in patients receiving long-term therapy. Nevertheless, it seems that many azole-resistant strains originated in the environment due to selection by azole fungicides used in agriculture. Azole resistance in A. fumigatus is associated mainly with mutations in the cyp51A gene, and among several mutations described, the most frequent is the mutation comprising a 34-bp tandem repeat (TR34) and the L98H alteration. Since azoles are the recommended first-line treatment for IPA, the emergence of azole resistance is worrisome and has been shown to be associated with an increased rate of clinical failure. For these reasons, routine antifungal susceptibility testing of clinical isolates has been recommended recently. Nevertheless, isolates are not always retrieved in culture, particularly for patients with hematological malignancies. Therefore, molecular detection of resistance may be a major advance for the management of patients with invasive aspergillosis.
The aim of this study will be to validate the new MycoGENIE A. fumigatus real-time PCR kit and to evaluate its performance on clinical samples for the detection of A. fumigatus and its azole resistance. This multiplex assay detects DNA from the A. fumigatus species complex by targeting the multicopy 28S rRNA gene and specific TR34 and L98H mutations in the single-copy number cyp51A gene of A. fumigatus.
The study will be performed in hematological patients with high-risk of developping IA during the course of chemotherapy. In these patients, bi-weekly detection of GM is routinely performed in all centers in France. The PCR will be performed on the samples used for GM detection. DNA will be extracted according to the manufacturer's protocol, using the MycoGENIE kit for AutoMag solution. Real-time PCR for the detection of A. fumigatus DNA will be performed using the MycoGENIE A. fumigatus real-time PCR kit (Ademtech, Pessac, France).
AI will be defined as proven or probable aspergillosis, according to EORTC criteria.
For each patient, clinical data will be collected in each center. These data include: EORTC classification, type and duration of antifungal treatments, results of GM tests, results of mycological cultures, and results of PCR tests (positivity and Ct values). For each patient a case report form (CRF) will be filled and transfered to the investigating center for analysis. Sensitivity, specificity, PPV and NPV of the PCR test will be calculated.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33000
- CHU Bordeaux, Groupe hospitalier
-
Dijon, France, 21000
- CHU de DIJON, Hôpital du bocage
-
Lille, France, 59000
- CHRU de Lille, Hopital Claude Huriez
-
Nantes, France, 44000
- CHU de Nantes, Hôpital de Moncousu
-
Paris, France, 75015
- Hôpital Necker - Enfants maladies (AP-HP)
-
Rennes, France, 35000
- CHU de Rennes, Hopital de Pontchaillou
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Adult Patients (≥ 18 years) hospitalized in onco hematologic unit or in hematopoietic stem cell transplantation (HSCT) unit
- Patients with acute leukemia undergoing induction for AML, ALL, chimotherapy with neutopenia >10 days or Patients undergoing allogeneic stem cell chemotherapy transplantation
- Patients with biweekly screening for GM detection in serum
Exclusion Criteria:
- Patient < 18 years-old (minor)
- Informed consent not available
- Patient without affiliation to French social insurance
- Patient without biweekly screening for GM detection in serum
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Hematological patients
Hematological patients at high risk for invasive aspergillosis
|
Performances diagnostic test of the real-time PCR ADEMTECH kit of DNA extraction and detection of Aspergillus fumigatus in serum samples in patients at high-risk for invasive aspergillosis (IA).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Performance of PCR for Aspergillosis diagnosis
Time Frame: 6 months
|
Determination of the performances (Sensitivity, specificity, PPV and NPV) of the kit
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Detection of azole resistance
Time Frame: 6 months
|
Detection of TR34 and L98H mutations in the A. fumigatus single-copy number gene cyp51A.
|
6 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Eric DANNAOUI, MD, PhD, Assistance Publique - Hôpitaux de Paris
- Principal Investigator: Marie-Elisabeth BOUGNOUX, MD, PhD, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
General Publications
- Suarez F, Lortholary O, Buland S, Rubio MT, Ghez D, Mahe V, Quesne G, Poiree S, Buzyn A, Varet B, Berche P, Bougnoux ME. Detection of circulating Aspergillus fumigatus DNA by real-time PCR assay of large serum volumes improves early diagnosis of invasive aspergillosis in high-risk adult patients under hematologic surveillance. J Clin Microbiol. 2008 Nov;46(11):3772-7. doi: 10.1128/JCM.01086-08. Epub 2008 Sep 24.
- Dannaoui E, Gabriel F, Gaboyard M, Lagardere G, Audebert L, Quesne G, Godichaud S, Verweij PE, Accoceberry I, Bougnoux ME. Molecular Diagnosis of Invasive Aspergillosis and Detection of Azole Resistance by a Newly Commercialized PCR Kit. J Clin Microbiol. 2017 Nov;55(11):3210-3218. doi: 10.1128/JCM.01032-17. Epub 2017 Aug 16.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- K-170102
- 2017-A01518-45 (Registry Identifier: ID-RCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Invasive Aspergillosis in Patients With Onco-haematological Diseases
-
University Hospital, GrenobleCompletedInvasive Aspergillosis | Voriconazole | Haematological Cancer PatientsFrance
-
Assistance Publique - Hôpitaux de ParisInstitut Pasteur, Paris FranceCompletedAspergillosis and Haematological MalignancyFrance
-
Universitaire Ziekenhuizen KU LeuvenCompletedInfluenza With Pneumonia | Aspergillosis InvasiveBelgium
-
Universitaire Ziekenhuizen KU LeuvenRecruitingInvasive Pulmonary Aspergillosis | Influenza With PneumoniaBelgium
-
Karolinska University HospitalCompletedThe Value of Procalcitonin in Patients With Suspected CandidemiaSweden
-
Fujian Shengdi Pharmaceutical Co., Ltd.Not yet recruitingPatients With Candidemia and/or Invasive Candidiasis
-
University Hospital, Basel, SwitzerlandClinical Trial Unit, University Hospital Basel, SwitzerlandCompletedCode Status Discussions With Medical In-patientsSwitzerland
-
Medical University of GrazMedical University of ViennaUnknownPrevalent OPG and RANKL Excession in Patients With CADAustria
-
National Institute of Diabetes and Digestive and...CompletedFoot Transepidermal Water Loss in Patients in NIDDM | Foot Dryness in Patients With NIDDM
-
Sohag UniversityRecruitingHelicobacter Pylori Infection in Patients With Chronic TonsillitsEgypt
Clinical Trials on DNA extraction and detection of Aspergillus fumigatus in serum samples
-
The First Affiliated Hospital with Nanjing Medical...UnknownGastric Cancer | Colorectal Cancer | Bladder CancerChina
-
The First Affiliated Hospital with Nanjing Medical...Fudan UniversityUnknownGastrointestinal Stromal TumorChina
-
Erasmus Medical CenterGilead SciencesCompletedAspergillosis, Invasive PulmonaryNetherlands
-
Assistance Publique - Hôpitaux de ParisHoffmann-La RocheCompletedFebrile Neutropenia | Severe Sepsis | EndocarditisFrance
-
Theodor Bilharz Research InstituteActive, not recruitingUrinary Bladder Neoplasms | MicrotiaEgypt
-
Centre Hospitalier Universitaire DijonUnknown
-
Assiut UniversityNot yet recruiting
-
Sohag UniversityRecruitingAngiotensin Converting Enzyme rs (1799752) Gene Polymorphism and Development of In-Stent Restenosis in Patients With Stable Coronary Artery DiseasesEgypt
-
Diskapi Yildirim Beyazit Education and Research...Active, not recruiting
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; Centre National...Unknown